Neoplasia/BPH

	A trial of risk-adapted prostate cancer screening in a federally supported health center network serving a high-risk population. Cancer Gann PH, Stackhouse N, Gastala N, Ma W, Wright ME, Watson K, Stepping C, King-Lee P, Xu Z, Patel T, Abern MR. PMID: 41761486 [PubMed - in process]
	Therapeutic potential of cytokine-induced killer cell therapy for renal cell carcinoma and prostate cancer. Cell Commun Signal Lee IT, Wang YL, Hong JH, Huang CY, Vo TTT, Lee WJ, Chiang CH. PMID: 41761243 [PubMed - as supplied by publisher]
	A multicenter study on preoperative WHO/ISUP grading of clear cell renal cell carcinoma using triphasic contrast-enhanced CT-based habitat imaging. BMC Med Imaging Zhang L, Shi N, Chen X, Shang S, Lu S, Li T, Liu Y, Han L, Ye J. PMID: 41761150 [PubMed - as supplied by publisher]
	Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial. Nat Med Mellema JJ, Stockem CF, Herberts C, Cheung SK, Vis DJ, van Rhijn BWG, Mertens LS, Boellaard TN, van Montfoort ML, Balduzzi S, de Feijter JM, van der Mijn JCK, Sharma S, El Naggar AC, Boormans JL, Franckena M, Meijer RP, Noteboom JL, Schaake EE, Robbrecht DGJ, Suelmann BBM, van der Heijden MS. PMID: 41760951 [PubMed - as supplied by publisher]
	Management of clinical failure after minimally invasive surgical therapies (MIST) for BPH: repeat MIST versus resection, enucleation or ablation-a narrative review from EAU endourology. World J Urol Bogatova S, Morozov A, Gauhar V, Lifshitz D, Sukhanov R, Ehrlich Y, Asali M, Krupinov G, Golan S, Somani BK, Herrmann TRW, Enikeev D. PMID: 41760943 [PubMed - in process]
	Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study. Urol Oncol Shah NJ, Sura S, Shinde R, Dai W, Wentworth C, Conkling P, Bupathi M, Vickery D, Perini R, Motzer RJ. PMID: 41760529 [PubMed - as supplied by publisher]
	ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapy. Eur Urol Focus Laccetti AL, Smith MR, Scher HI, Nowfar S, Einstein D, Martin B, Adorjan P, Dissanayake M, Verholen F, Gao X. PMID: 41760423 [PubMed - as supplied by publisher]
	Development and Validation of Radiomics and Clinical Models for Predicting Gleason Grades in Prostate Cancer Across Tumor Subregions and Clinical Factors: A Dual-Center Study. Acad Radiol Liu L, Yin P, Bao M, Wang J, Han B, He Y, Lu F, Yin L. PMID: 41760414 [PubMed - as supplied by publisher]
	Cost-Effectiveness of PSMA PET/CT as Single Procedure for Diagnosis and Staging High-Grade Prostate Cancer: A Single Center Experience. In Vivo Pepe P, Pepe L, Pepe G, Privitera R. PMID: 41760330 [PubMed - in process]
	The Prognostic Role of Baseline and Early Dynamics of Peripheral Blood Cell Ratios in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab. In Vivo Fiala O, Tkadlecova M, Kopecky J, Hosek P, Studentova H, Vocka M, Mateju M, Lohynska R, Sikova D, Stransky P Jr, Kucera R, Zemankova A, Spisarova M, Priester P, Kouril J, Buchler T, Grmelova L, Melichar B, Poprach A. PMID: 41760301 [PubMed - in process]
	Urinary Amino Acid Profiling as a Non-invasive Diagnostic and Risk Stratification Tool in Prostate Cancer. In Vivo Zdobinska T, Luksanova H, Duskova K, Priman O, Slavenko M, Babjuk M, Vesely S. PMID: 41760295 [PubMed - in process]
	Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial. Cell Rep Med Ager CR, Obradovic A, McCann P, Chaimowitz M, Wang ALE, Shaikh N, Shah P, Pan SS, Laplaca CJ, Virk RK, Hill JC, Jugler C, DeFranco G, Bhattacharya N, Copple KR, Nguyen P, Scher HI, DeCastro GJ, Anderson CB, McKiernan JM, Spina CS, Stein MN, Runcie K, Drake CG, Califano A, Dallos MC. PMID: 41759531 [PubMed - as supplied by publisher]
	Unravelling Salvage Re-irradiation for Locally Recurrent Prostate Cancer: Challenges and Complexities. Clin Oncol (R Coll Radiol) Biolatti LV, Ismail N, Devi A, Zhong J, Bleaney CW, Choudhury A. PMID: 41759222 [PubMed - as supplied by publisher]
	Post-translational modifications: Principal regulators of bladder cancer. Mol Biol Rep Deng Z, Yan Z, Chen Z. PMID: 41758403 [PubMed - in process]
	Exploring the potential mechanisms of hydroquinone on bladder cancer using network toxicology, Mendelian randomization analysis, molecular docking, and molecular dynamics simulations. Discov Oncol Li Y, Ma Y, Lai J, Wan Q, Li J, Wu J. PMID: 41758391 [PubMed - as supplied by publisher]
	External validation and comparison of nomograms for prediction of long-term disease recurrence and survival for bladder cancer patients who undergo radical cystectomy. Minerva Urol Nephrol Benijts R, Akand M, Tipirdamaz M, Mennes J, Baekelandt L, Everaerts W, Albersen M, VAN Poppel H, Joniau S, VAN DER Aa F. PMID: 41757874 [PubMed - as supplied by publisher]
	Comparative Study of Chemically Induced Renal Mesenchymal and Mammary Tumors in Female Sprague-Dawley and Wistar Rats. Toxicol Pathol Duarte MCO, Oliveira ISQ, Romualdo GR, Rodrigues MAM, da Silva TC, Cogliati B, Barbisan LF. PMID: 41757734 [PubMed - in process]
	Prediction Analysis of Microarray of 50 genes (PAM50) classifier validated for predicting prostate cancer progression in active surveillance: Miami Active Surveillance Trial (MAST). BJU Int Malpani A, Ryan JT, Yu H, Soodana-Prakash N, Khandekar A, Ajami T, Williams A, Szczotka Z, Alshalalfa M, Hao Y, Davicioni E, Swain S, Kryvenko O, Pra AD, Stoyanova R, Gaston S, Pollack A, Mahal BA, Abramowitz M, Nahar B, Ritch CR, Kava B, Gonzalgo ML, Parekh DJ, Punnen S. PMID: 41757539 [PubMed - as supplied by publisher]
	A rare case of ectopic cushing's syndrome caused by renal neuroendocrine tumor. J Diabetes Metab Disord Sehatpour F, Panahi N, Ramezani-Binabaj M, Yahyazadeh SR, Sefidbakht S, Tavangar SM, Manafi-Farid R, Soltani A, Radmard AR, Mirtaher FS, Pejman Sani M, Sajjadi-Jazi SM. PMID: 41757383 [PubMed]
	Registry-based randomised phase II study of Enzalutamide versus Abiraterone: assessing cognitive function in eLderly patients with metastatic castration-resistant Prostate cancer (REAL-Pro). ESMO Real World Data Digit Oncol Anton A, Steer C, Arasaratnam M, Torres J, Weickhardt A, Warren M, Mislang ARA, Azad AA, Linton A, Smith A, Rai S, Hong W, Gibbs P, Tran B. PMID: 41757352 [PubMed]

Articles 1 - 20 / 185867

Page 1 of 9294



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy